Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-In-Human, Open-Label, Dose Escalating, Non-Randomized Study to Assess the Safety and Tolerability of a New Timolol Sustained Release Intraocular Implant (TimoD) in Subjects With Primary Open Angle Glaucoma With Pseudophakia

NCT06321562 is registered in ClinicalTrials.gov with EyeD Pharma as lead sponsor.

NCT NCT06321562
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06321562 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-In-Human, Open-Label, Dose Escalating, Non-Randomized Study to Assess the Safety and Tolerability of a New Timolol Sustained Release Intraocular Implant (TimoD) in Subjects With Primary Open Angle Glaucoma With Pseudophakia
Lead sponsor
EyeD Pharma
Phase
Phase 1
Overall status
Terminated
Start date
March 1, 2023
Completion date
June 26, 2025
Enrollment
1 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

primary open-angle glaucoma